How to appeal an Aetna specialty biologics denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna specialty biologics denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for specialty biologics
Cited policy: Aetna Clinical Policy Bulletin - Tumor Necrosis Factor Antagonists
Confirmed diagnosis + age criteria + inadequate response to >=3 months csDMARD (RA/PsA) OR >=2 NSAIDs at max dose for >=4 weeks (AS) OR moderate-severe psoriasis (BSA>=10%, special site, or PASI>=12). TB screening + Hep B/C screening required.
How Aetna denies specialty biologics — and how to counter it
Where Aetna pushes back: 1) Step therapy: trial preferred biosimilar (Hyrimoz/Cyltezo) before non-preferred; 2) Otezla not tried in psoriasis before requested biologic (CVS Caremark commercial); 3) Missing TB/Hep screen; 4) MTX trial duration <3 months or dose not optimized.
Counter-arguments that hold up: CPB 0314 explicitly accepts intolerance/AE/contraindication as therapy-failure equivalent — cite specific AE. For special-site psoriasis (genitalia, palms/soles, face, scalp >=30%), AAD 2020 supports biologic regardless of BSA<10%. CVS Caremark Continuity of Care 90-day grandfather. State step-therapy override laws (NY §4903, TX SB 1216, CA HSC §1367.241): exception if prior failure documented in any plan, contraindication, expected ineffective, or stable on current.
What Aetna typically denies for specialty biologics
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For specialty biologics, expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the specialty biologics treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Humira
- Enbrel
- Remicade
- Stelara
- Skyrizi
- Cosentyx
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna specialty biologics denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for specialty biologics?
For specialty biologics, Aetna most often denies on: 1) Step therapy: trial preferred biosimilar (Hyrimoz/Cyltezo) before non-preferred; 2) Otezla not tried in psoriasis before requested biologic (CVS Caremark commercial); 3) Missing TB/Hep screen; 4) MTX trial duration <3 months or dose not optimized. The strongest counters: CPB 0314 explicitly accepts intolerance/AE/contraindication as therapy-failure equivalent — cite specific AE. For special-site psoriasis (genitalia, palms/soles, face, scalp >=30%), AAD 2020 supports biologic regardless of BSA<10%. CVS Caremark Continuity of Care 90-day grandfather. State step-therapy override laws (NY §4903, TX SB 1216, CA HSC §1367.241): exception if prior failure documented in any plan, contraindication, expected ineffective, or stable on current.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Specialty biologics appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com